摘要
有限的干预手段使得肺癌患者面临着欠佳的预后。近年来免疫治疗成为了继手术、放疗、化疗等治疗后非小细胞肺癌(non-smallcell lung cancer,NSCLC)的新型研究方向。以程序性死亡分子1(programmed death-1,PD-1)/程序性死亡分子1配体(programmed death-1 ligand,PD-L1)为代表的免疫检查点在肿瘤的发生发展中起到重要作用,证实了其抑制剂抗PD-1单抗在晚期非小细胞肺癌患者生存的相关性,以及PD-L1作为疗效预测的生物标记物的潜力。目前,nivolumab和pembrolizumab已经开启了在非小细胞肺癌治疗上的先河。FDA于2015批准了上述两种免疫抑制剂在非小细胞肺癌二线治疗中的临床应用。本文对PD-1/PD-L1信号通路、抗PD-1单抗在非小细胞肺癌中的作用机制、临床现状及展望进行综述。
Limited therapies lead to an undesirable prognosis to patients with lung cancer. In recent years, immune therapy has become a new direction in the treatment of non-small cell lung cancer in addition to surgery, radiotherapy, chemotherapy and so on. The immune checkpoints represented by programmed death-1 （PD-1） and programmed death-1 ligand （PD-L1） have a significant influence on the development of cancer, indicating the relationship between the inhibitors like anti-PD-1/PD-L1 monoclonal antibody and survival, and the potential to PD-L1 as biomarker for curative effect. At present, nivolumab and perbrolizumab have created another way focusing on non-small cell lung cancer. In 2015, the FDA approved the two aboved-mentioned immune inhibitors as the second-line treatment for patients suffering non-small cell lung cancer. In this article, we summarized the signal pathway of PD-1/PD-L1, and action mechanism of anti-PD-1 monoclonal antibody in non-small cell lung cancer, as well as its clinical current status and future direction.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第17期1967-1972,共6页
Chinese Journal of New Drugs
